Lantern Pharma Inc
LTRN
Get informed when a big investor buys or sells
+ FollowMarket Cap$45.8M
Close$
$0.68
80.1% downside
Current Fair Value
80.1% downsideOvervalued by 80.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $45.80 Million |
|---|---|
| Enterprise Value | $40.95 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.57 |
| Beta | 2.1 |
| Outstanding Shares | 11,253,030 |
Return
| Return on Equity | -496799.65% |
|---|---|
| Return on Assets | -236993.93% |
| Return on Invested Capital | -482.16% |
Valuation & Multiples
| P/E Ratio | -2.54 |
|---|---|
| PEG | 9.54 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -2.46 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0.02 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 15, 2026
EPS Estimate
$-0.36
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
August 12, 2026
EPS Estimate
$-0.38
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 18.99%▼ 2.06% |
|---|---|
| Total Invested | $2.83M▼ 58.97% |
| Investors Holding | 32▼ 3.00% |
ESG Score
No data
About Lantern Pharma Inc
13 employeesLantern Pharma (LTRN) is a clinical-stage biopharmaceutical company innovating the repurposing, revitalization and development of precision therapeutics in oncology. It leverages advances in machine learning, genomics, and artificial int...